Cannabigerol
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07577999 | Jul 2027 → May 2028 expected | urinary bladder cancer | Stanford University | Not yet recruiting | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT05324982 | Aug 2022 → Dec 2025 overdue | — | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 1 | NCT05257044 | Mar 2022 → Nov 2023 | — | Washington State University | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07592390 | May → Dec 2026 expected | attention deficit-hyperactivity disorder | University of Southern Santa Catarina | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07839455 | Nov 2025 → Oct 2026 expected | psoriasis | Federal University of Latin American Integration | Active not recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07821840 | Nov 2026 → Mar 2027 expected | generalized anxiety disorder | Associação Pan-Americana Multidisciplinar de Endocanabinologia | Not yet recruiting | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT04859296 Comparator | Feb 2023 → Dec 2025 overdue | substance abuse | University of California, Los Angeles | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06115603 Comparator | Dec 2024 → Jul 2026 overdue | attention deficit-hyperactivity disorder | University of Arkansas, Fayetteville | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04989413 Comparator | Oct 2022 → Feb 2025 | migraine disorder | Hospital Israelita Albert Einstein | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cannabigerol | “Participants assigned to this arm will receive an oral full-spectrum cannabis extract containing cannabidiol (CBD), cannabigerol (CBG), and delta-9-tetrahydrocannabinol (THC)...” NCT07839455 ↗8“The purpose of the present study is to examine the pharmacokinetics and pharmacodynamics of cannabigerol (CBG; CHI-914), a naturally occurring chemical constituent of the...” NCT05324982 ↗ “Full-spectrum Cannabis sativa extract containing cannabigerol (CBG) 30 mg/mL, cannabidiol (CBD) 30 mg/mL, and tetrahydrocannabinol (THC) 3 mg/mL, administered sublingually for...” NCT07592390 ↗ “analgesic, appetite-stimulating, and subjective effects of cannabigerol (CBG) alone” NCT04859296 ↗ |
| Known as | CBG | “Participants assigned to this arm will receive an oral full-spectrum cannabis extract containing cannabidiol (CBD), cannabigerol (CBG), and delta-9-tetrahydrocannabinol (THC)...” NCT07839455 ↗6“The purpose of the present study is to examine the pharmacokinetics and pharmacodynamics of cannabigerol (CBG; CHI-914), a naturally occurring chemical constituent of the...” NCT05324982 ↗ “Full-spectrum Cannabis sativa extract containing cannabigerol (CBG) 30 mg/mL, cannabidiol (CBD) 30 mg/mL, and tetrahydrocannabinol (THC) 3 mg/mL, administered sublingually for...” NCT07592390 ↗ “The goal of this clinical trial is to evaluate the effects of Cannabigerol (CBG) on indicators of Attention-Deficit/Hyperactivity Disorder (ADHD) in a sample of participants...” NCT06115603 ↗ “Participants receive CannaRiver CBD Calm, an oral/sublingual broad-spectrum cannabinoid tincture containing cannabidiol (CBD), cannabinol (CBN), and cannabigerol (CBG), at 0.5...” NCT07821840 ↗ “To evaluate the effect of the cannabidiol (CBD) + cannabigerol (CBG) + tetrahydrocannabinol (THC) up to 133/66/4mg daily versus placebo as adjuvant treatment in chronic...” NCT04989413 ↗ |
| Known as | CHI-914 | “The purpose of the present study is to examine the pharmacokinetics and pharmacodynamics of cannabigerol (CBG; CHI-914), a naturally occurring chemical constituent of the...” NCT05324982 ↗ |
| Modality | Small molecule | — CHEMBL497318 ↗ |
| Route | Other | “Vaporized CBG (5 mg)” NCT04859296 ↗ |